Aytu BioPharma Outlines FY27 Operating Plan with $49M-$54M Budget and Targets 66%-67% Gross Margin in Q4
Aytu BioPharma (NASDAQ:AYTU) has outlined a fiscal year 2027 operating expense plan ranging between $49 million to $54 million. The company is targeting gross margins of 66-67% for the fourth quarter of FY27, reflecting its focus on improving profitability and operational efficiency. The guidance comes after Aytu reported a strong fiscal year-end in Q4 FY2026, with positive adjusted EBITDA results. CEO Joshua Disbrow highlighted that EXXUA continued to build momentum while the ADHD business outperformed expectations. These developments signal improved performance across key therapeutic areas and better-than-expected financial outcomes. The company's strategic focus on cost management and gross margin expansion suggests a disciplined approach aimed at driving long-term value for shareholders.
